Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer

Cancer Letters

Volumn 128, Issue 2, 1998, Pages 211-218

  Sugiyama, Toru ^a   Yakushiji, Michiaki ^a   Nishida, Takashi ^a   Ushijima, Kimio ^a   Okura, Naofumi ^a   Kigawa, Junzo ^b   Terakawa, Naoki ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatin; CPT 11; Recurrent ovarian cancer

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 0032547039     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00065-2     Document Type: Article

References (40)

1. R.F. Ozols, S.C. Rubin, A.J. Dembo et al., Epithelial ovarian cancer, in: W.J. Hoskins, C.A. Perez, R.C. Young (Eds.), Principles of Gynaecologic Oncology, J.B. Lippincott, Philadelphia, PA, 1992, pp. 731-781.
2. Gruppo Interegionale Cooperativo Oncologio Ginecologia Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet. 2:1987;353-359.
3. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
4. Nitta K., Yokokura T., Sawada S.et al. Antitumor activity of novel derivatives of camptothecin (in Japanese). Gan To Kagaku Ryoho. 14:1987;850-857.
5. Wang J.C. DNA topoisomerases: why so many? J. Biol. Chem. 6:1991;6659-6662.
6. Champoux J. Evidence for an intermediate with a singlestrand break in the reaction catalyzed by the DNA untwisting enzyme. Proc. Natl. Acad. Sci. USA. 73:1976;3488-3491.
7. Lynn R.M., Bjornsti M.A., Caron P.R.et al. Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of saccharomyces cerevisiae DNA topoisomerase-I. Proc. Natl. Acad. Sci. USA. 86:1989;3559-3563.
8. L.F. Liu, P. D'arpa, Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance, in: V. DeVita, S. Hellman, S. Rosenberg (Eds.), Important Advances in Oncology, J.B. Lippincott, Philadelphia, PA, 1992, pp. 79-89.
9. Hsiang Y.H., Liu L.F., Wall M.E.et al. DNA topoisomerase-I mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 49:1989;4385-4389.
10. Shimada Y., Yoshino M., Wakui A.et al. CPT-11 gastrointestinal cancer study group. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J. Clin. Oncol. 11:1993;909-913.
11. Negoro S., Fukuoka M., Niitani H.et al. An early phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer (abstract). Proc. Am. Soc. Clin. Oncol. 10:1991;241.
12. Masuda N., Fukuoka M., Kusunoki Y.et al. A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. 10:1992;1225-1229.
13. Fukuoka M., Niitani H., Suzuki A.et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J. Clin. Oncol. 10:1992;16-20.
14. Masuda N., Fukuoka M., Kudoh S.et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small lung cancer. J. Clin. Oncol. 12:1994;90-96.
15. Okamoto H., Nagatomo A., Kunitoh H.et al. A combination phase I-II study of carboplatin/irinotecan plus G-CSF with the Calvert equation in patients with advanced non-small-cell lung cancer (abstract). Proc. Am. Soc. Clin. Oncol. 14:1995;A1150.
16. Ohno R., Okada K., Masaoka T.et al. An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1990;1907-1912.
17. Futasuki K., Wakui A., Nakao I.et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer (in Japanese). Gan To Kagaku Ryoho. 21:1994;1033-1038.
18. Clavel M., Mathieu-Boue A., Dumortier A. Phase II study of CPT-11 administered as a daily infusion for 3 consecutive days (abstract). Proc. Am. Assoc. Cancer Res. 33:1992;262.
19. Takeuchi S., Takamizawa H., Takeda Y.et al. An early phase II study of CPT-11 in gynecologic cancers. Research group of CPT-11 in gynecologic cancers (in Japanese). Gan To Kagaku Ryoho. 18:1991;579-584.
20. Takeuchi S., Dobashi K., Fujimoto S.et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research group of CPT-11 in gynecologic cancers (in Japanese). Gan To Kagaku Ryoho. 18:1991;1681-1689.
21. Mori H., Itoh N., Kondoh H.et al. Treatment of recurrent gynecologic malignancies with a new camptothecin derivative. Eur. J. Cancer. 28:1992;613-617.
22. T. Sugiyama, S. Takeuchi, K. Noda et al., Phase I study of irinotecan (CPT-11) in combination with cisplatin in cervical and ovarian carcinoma (abstract), Proceedings of the Fifth Conference on DNA Topoisomerases in Therapy, New York, 1994, p. 47.
23. Chevallier B., Lhomme C., Dieras V.et al. Phase II trial of CPT-11 in advanced cervical carcinoma (abstract). Proc. Am. Soc. Clin. Oncol. 14:1995;267.
24. Verschraegen C.F., Levy T., Kudelka A.P.et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 15:1997;625-631.
25. Kano Y., Suzuki K., Akutsu M.et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int. J. Cancer. 50:1992;604-610.
26. ASCO Ad Hoc Committee American Society of Clinical Oncology recommendation for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J. Clin. Oncol. 12:1994;2471-2508.
27. Oken M.M., Creech R.H., Tormey D.C.et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
28. Sakata Y., Suzuki H., Kamataki T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (in Japanese). Gan To Kagaku Ryoho. 21:1994;1241-1244.
29. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:1958;457-481.
30. Simon R. Confidence intervals for reporting results of clinical trials. Ann. Intern. Med. 105:1986;429-435.
31. Kawano Y., Aonuma M., Hirota Y.et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51:1991;4187-4191.
32. Takeshima N., Hirai Y., Shimizu Y.et al. A report on a case with recurrent ovarian clear cell adenocarcinoma (peritoneal dissemination) who exhibited a remarkable response to CPT-11. J. Jpn. Soc. Cancer Ther. 30:1995;705-711.
33. Shimizu Y., Umezawa S., Hasumi K. Combination of CPT-11 (CPT) and mytomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant (abstract). Proc. Am. Soc. Clin. Oncol. 15:1996;282.
34. Kudoh S., Fukuoka M., Takada M.et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res. 84:1993;203-207.
35. Trimble E.L., Adams J.D., Vena D.et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11:1993;2405-2410.
36. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D.et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12:1994;2654-2666.
37. Thigpen J.T., Blessing J.A., Ball H.et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group Study. J. Clin. Oncol. 12:1994;1748-1753.
38. Kaye S.B., Piccart M., Aapro M.et al. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. Eur. J. Cancer. 31A(Suppl.):1995;S14-S17.
39. Kavanagh J.J., Kudelka A.P., Gonzalez de Leon C.et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. 2:1996;837-842.
40. Creemer G.J., Bolis G., Gore M.et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14:1996;3056-3061.